Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. - Wikidata - awgldk - TriplyDB

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

http://www.wikidata.org/entity/Q33786865

about

Effects of PTH on osteocyte function Catabolic and anabolic actions of parathyroid hormone on the skeleton Osteoporosis and obesity: Role of Wnt pathway in human and murine models Novel biological markers of bone: from bone metabolism to bone physiology Anorexia nervosa, obesity and bone metabolism Parathyroid hormone: anabolic and catabolic actions on the skeleton Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation The effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes.Association study of polymorphisms in the SOST gene region and parameters of bone strength and body composition in both young and elderly men: data from the Odense Androgen Study.Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes.Sclerostin.Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women Serum estradiol levels are inversely associated with cortical porosity in older men.Oxytocin and bone The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors Sclerostin and Dickkopf-1 in renal osteodystrophy.Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D 2 (300,000 IU).Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b Regulation of circulating sclerostin levels by sex steroids in women and in men.Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors.Circulating sclerostin in disorders of parathyroid gland function.Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.Association between sclerostin and bone density in chronic spinal cord injury Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered.The effect of single extremity-vibration on the serum sclerostin level.Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation.Serum sclerostin and risk of hip fracture in older Caucasian women Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.Circulating sclerostin is elevated in short-term and reduced in long-term SCI.Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.Osteocytes and Skeletal Pathophysiology Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels Sclerostin as a novel marker of bone turnover in athletes.Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry

P2860

Q24631082-66A7C381-FCA5-4B26-B686-EF566292AFD1 Q26828873-A17DD34C-31F7-4219-85EC-549C4A2840B7 Q27026535-262E413C-7604-4A9E-82BA-61812ECACF0B Q28067712-64652881-09C9-4ECD-B32B-2CEB7BD4EF1C Q33554695-119322E9-C139-435F-AFEA-0BC766871C67 Q33609126-EC1E93D9-82D4-41FC-8B85-6F30911B6A40 Q33739417-D233DC01-F089-43E9-9837-41BA86683436 Q33905129-0C919B24-1C06-48E1-8B44-9C73FE620280 Q34072806-1E211C6E-C246-4423-8354-6632FF5073A3 Q34206461-D9A99915-162A-45CA-9541-ED22928CB92D Q34211729-EB866E72-360F-46AE-9C9B-86AFCA096483 Q34262453-0669A205-C25E-4C25-997E-07A242E19372 Q34313671-BB3CC69F-B9B7-4100-893B-4035B39F4985 Q34356431-0C3C3514-4F5C-47C2-9B1C-FCDFC90AA404 Q34428195-5B23F612-ADB8-427E-B557-65BD8FEDD09A Q34751932-8522162E-5134-4D40-9D03-35E5BB0EE3D9 Q34761795-8B866CDB-7971-47D0-8E5D-BEA8E71E4B84 Q35053384-ED783D02-4952-4A49-8B0E-ADCD61B2FD59 Q35078333-BEBD6A35-073A-428C-9566-10B201B1C4CE Q35094024-4B885D78-DBC6-42AE-A422-33F0DD934389 Q35101832-28347B1F-F490-4D3B-9B82-DDE73A5E6B3B Q35110851-680DE788-AB85-4597-B7F5-BA5D88630E62 Q35229894-569530E5-D55E-4883-9671-116BFEC01EA2 Q35230055-62D72107-B102-4DAB-BCE3-781AD0BA509C Q35260816-131E488F-3DBE-478B-BBD3-E7F42F460FAA Q35597871-230EAA51-6237-4FB9-876C-C1BB28C42AC1 Q35635751-83B5486E-D8CF-46F6-868A-9D6E6CFD7ED9 Q35782783-7312135E-C8DA-4092-9931-3ABEE779CD62 Q35831180-9052DB45-BBD8-4327-BEE9-1C81302160BE Q35968335-AA0EFA37-7328-49E0-AE3D-A59286EFAF69 Q36020434-14B8BC4E-61FA-4DD5-9587-0C98961EB391 Q36069858-1E53E637-F806-49EF-9AF9-A16003CCAAE3 Q36117524-6F8A8375-A726-4C4E-8411-882A2BDA4D19 Q36143807-39CE85C8-989C-4AC8-A6EC-FFB339A57C2B Q36143916-B77F1367-BF36-42E0-B9C2-88BA9E3B65B7 Q36193227-9063C92B-F0FE-487F-AD78-1417B78EE049 Q36357606-07371156-C955-4236-8B92-79F89EEBE948 Q36561855-B4A564D2-8CAC-42FA-83EF-A6F20C0A9FD3 Q36606834-A6BF59EC-B4BA-447B-BC3C-5DDADFA95D1F Q36685956-D75B14B5-DFF9-42F4-9F2C-440AD2D776D7

P2860

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

http://www.wikidata.org/entity/Q33786865

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Serum sclerostin levels negati ...... index in postmenopausal women.

@ast

Serum sclerostin levels negati ...... index in postmenopausal women.

@en

type

label

Serum sclerostin levels negati ...... index in postmenopausal women.

@ast

Serum sclerostin levels negati ...... index in postmenopausal women.

@en

prefLabel

Serum sclerostin levels negati ...... index in postmenopausal women.

@ast

Serum sclerostin levels negati ...... index in postmenopausal women.

@en

P1433

Q33786865-CB97AE66-B534-43D1-965D-0B86B9872B7A

P1476

Q33786865-54FB12AA-A368-418C-93CF-FFEAF60726DC

P2093

Q33786865-0A2788E2-63A2-47BA-BE6C-09F117901AA8

Q33786865-4A9033FA-AF97-4CCA-9ABF-52D3B7F3CAF9

Q33786865-9B926D17-6A5C-4CED-A6C3-75FC74C0FFCE

Q33786865-D7779CC6-1267-47D4-935B-B7E620EA4DC9

P2860

Q33786865-04ADB42C-9CC0-4628-B544-2B7342390FED

Q33786865-1FED5A6D-3ABC-43E3-A17B-C3D5A686D582

Q33786865-30C55B8D-8E67-4A96-BB4E-7913F475D63B

Q33786865-402242C9-249E-44C5-AF71-11288E2A8199

Q33786865-4B5F8DC6-0EB0-4FCC-ACAB-B5E1DD4A7800

Q33786865-4C38319F-C5B1-4B16-9F42-7D9C54F009AC

Q33786865-4EF2FD84-DC5F-4323-9622-2BD76B5CF68A

Q33786865-6F0D277A-4129-42B2-9F73-51DD5CAAF4AC

Q33786865-83144077-C566-4D76-B344-DD22E0871069

Q33786865-83EA1815-40F7-466C-B7C4-D2372058A588

P304

Q33786865-BD15D389-C48B-4D75-B425-00DEEA93D82F

P31

Q33786865-2ED07805-A21D-425E-919F-2219494CB854

P356

Q33786865-5ECC20F8-F8A4-4149-8373-0F913CAAEE44

P407

Q33786865-5A407E2D-11B9-4E00-A23D-63E90C24926E

P433

Q33786865-03F069B6-E564-4660-8495-0857E91DD6E2

P478

Q33786865-025F817A-0E4D-4BF3-A935-767E74C95FD4

P577

Q33786865-E7C269C1-6A24-4194-B093-B646804A5AE1

P698

Q33786865-65AEBAA7-336C-45A2-9C0C-EA4A8B02F1FE

P932

Q33786865-FFF65205-151B-4E35-A1D9-BB12A833579A

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Serum sclerostin levels negati ...... index in postmenopausal women.

@en

P2093

Faryal S Mirza

http://www.w3.org/2001/XMLSchema#string

I Desmond Padhi

http://www.w3.org/2001/XMLSchema#string

Joseph A Lorenzo

http://www.w3.org/2001/XMLSchema#string

Lawrence G Raisz

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

Wnt/beta-catenin signaling in development and disease

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity

P304

1991-1997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2009-2283

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20156921

http://www.w3.org/2001/XMLSchema#string

P932

2853994

http://www.w3.org/2001/XMLSchema#string